Diagnosticos da America SA
BOVESPA:DASA3
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.34
10.55
|
Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DASA3 stock under the Base Case scenario is 14.82 BRL. Compared to the current market price of 2.34 BRL, Diagnosticos da America SA is Undervalued by 84%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Diagnosticos da America SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DASA3 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Diagnosticos da America SA
Balance Sheet Decomposition
Diagnosticos da America SA
Current Assets | 9.2B |
Cash & Short-Term Investments | 3B |
Receivables | 5.4B |
Other Current Assets | 827.4m |
Non-Current Assets | 18.9B |
Long-Term Investments | 11m |
PP&E | 6.3B |
Intangibles | 10.5B |
Other Non-Current Assets | 2.1B |
Current Liabilities | 5.6B |
Accounts Payable | 1.3B |
Accrued Liabilities | 1.2B |
Other Current Liabilities | 3.1B |
Non-Current Liabilities | 15.3B |
Long-Term Debt | 12.1B |
Other Non-Current Liabilities | 3.3B |
Earnings Waterfall
Diagnosticos da America SA
Revenue
|
14.8B
BRL
|
Cost of Revenue
|
-10.8B
BRL
|
Gross Profit
|
4B
BRL
|
Operating Expenses
|
-2.9B
BRL
|
Operating Income
|
1B
BRL
|
Other Expenses
|
-2B
BRL
|
Net Income
|
-998.4m
BRL
|
Free Cash Flow Analysis
Diagnosticos da America SA
BRL | |
Free Cash Flow | BRL |
The company reported a 9% increase in gross revenue to over BRL 2 billion, driven by a 4% rise in patient volume and better segment mix. Efficiency improvements, such as closing low-revenue units and digitalization, led to a 14% increase in adjusted gross profit and a 1.7 percentage point gain in adjusted gross margin. EBITDA grew 27%, with a 2.4 percentage point margin expansion. A capital infusion of BRL 1.5 billion significantly reduced net debt. The company's operational excellence program continues, aiming for sustainable, long-term growth.
What is Earnings Call?
DASA3 Profitability Score
Profitability Due Diligence
Diagnosticos da America SA's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Diagnosticos da America SA's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
DASA3 Solvency Score
Solvency Due Diligence
Diagnosticos da America SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Score
Diagnosticos da America SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DASA3 Price Targets Summary
Diagnosticos da America SA
According to Wall Street analysts, the average 1-year price target for DASA3 is 7.69 BRL with a low forecast of 2.93 BRL and a high forecast of 21.84 BRL.
Dividends
Current shareholder yield for DASA3 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Diagnósticos da América SA engages in medical diagnostics services and in the business of research and development of diagnostic tests and their application to the medical practice. The company is headquartered in Barueri, Sao Paulo. The company went IPO on 2004-11-19. The Company’s services are structured into three units: Ambulatory and Hospital, which provides clinical analyses and diagnostic imaging; Laboratory support, which provides services for small and medium-sized laboratories, and Public Health Sector, in which the Company operates through the CientificaLab brand, which focuses on providing auxiliary diagnostic support services for the public health sector. In addition, the Company is engaged in activities related to tests in food and substances to evaluate risks for the human being; import, for its own use, of medical-hospital equipment, sets for diagnostics and related material in general, and granting and administration of business franchising, including advertising and publishing fund, training and selection of labor, supplying of equipment and research material suppliers, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one DASA3 stock under the Base Case scenario is 14.82 BRL.
Compared to the current market price of 2.34 BRL, Diagnosticos da America SA is Undervalued by 84%.